Back to top
more

West Pharmaceutical Services (WST)

(Delayed Data from NYSE)

$318.02 USD

318.02
984,748

+0.10 (0.03%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $318.06 +0.04 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Teleflex (TFX) Stock for Now

Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.

Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves

Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.

Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall

Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.

Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows

Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.

NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down

NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.

Cardiovascular Systems (CSII) Q1 Loss Wider Than Expected

Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.

Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates

Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.

SmileDirectClub (SDC) Q3 Earnings Lag Estimates, Margin Grows

SmileDirectClub (SDC) registered a year-over-year decline in revenues in the third quarter due to lower unique aligner shipment.

Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass

Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.

Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up

Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.

AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat

AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.

Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3

Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.

Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up

Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.

Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up

Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.

Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline

Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.

LHC Group (LHCG) Q3 Earnings Match Estimates, Down Y/Y

LHC Group's (LHCG) third-quarter results benefit from organic growth in both home health and hospice admissions.

Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3

Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.

Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag

Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.

Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up

Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.

Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up

Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.

Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top

Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.

Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down

Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.

BD (BDX) Beats on Q4 Earnings and Revenues, FY22 View Issued

Each of BD's (BDX) core units witnesses strong revenue growth in the fiscal fourth quarter, driving up the overall top line.